Stay updated on Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows Revision: v3.4.2 and a funding/status notice was removed. These are administrative updates that do not affect study data, eligibility criteria, outcomes, or how users interact with the page.SummaryDifference0.4%

- Check21 days agoChange DetectedNotice about government funding and NIH Clinical Center status added. Site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle and updated page metadata to reflect the latest revision (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). Removed the older metadata entries (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedRevision notes updated: v3.3.4 added and v3.3.3 removed.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Florida location to the study Locations section and removed the separate Florida Locations entry; page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check92 days agoChange DetectedThe Publications section now clarifies that publications are provided voluntarily and relate to the study results. A revision note 'Revision: v3.3.2' was added.SummaryDifference0.1%

Stay in the know with updates to Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.